Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
Chuanxin Zhong,Nanxi Li,Shengzheng Wang,Dijie Li,Zhihua Yang,Lin Du,Guangxin Huang,Haitian Li,Wing Sze Yeung,Shan He,Shuting Ma,Zhuqian Wang,Hewen Jiang,Huarui Zhang,Zhanghao Li,Xiaoxin Wen,Song Xue,Xiaohui Tao,Haorui Li,Duoli Xie,Yihao Zhang,Zefeng Chen,Junqin Wang,Jianfeng Yan,Zhengming Liang,Zongkang Zhang,Zhigang Zhong,Zeting Wu,Chao Wan,Chao Liang,Luyao Wang,Sifan Yu,Yuan Ma,Yuanyuan Yu,Fangfei Li,Yang Chen,Baoting Zhang,Aiping Lyu,Fuzeng Ren,Hong Zhou,Jin Liu,Ge Zhang
DOI: https://doi.org/10.1038/s41467-024-52965-4
2024-10-04
Abstract:Excessive glucocorticoid (GC) action is linked to various metabolic disorders. Recent findings suggest that disrupting skeletal GC signaling prevents bone loss and alleviates metabolic disorders in high-fat diet (HFD)-fed obese mice, underpinning the neglected contribution of skeletal GC action to obesity and related bone loss. Here, we show that the elevated expression of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), the enzyme driving local GC activation, and GC signaling in osteoblasts, are associated with bone loss and obesity in HFD-fed male mice. Osteoblast-specific 11β-HSD1 knockout male mice exhibit resistance to HFD-induced bone loss and metabolic disorders. Mechanistically, elevated 11β-HSD1 restrains glucose uptake and osteogenic activity in osteoblast. Pharmacologically inhibiting osteoblastic 11β-HSD1 by using bone-targeted 11β-HSD1 inhibitor markedly promotes bone formation, ameliorates glucose handling and mitigated obesity in HFD-fed male mice. Taken together, our study demonstrates that osteoblastic 11β-HSD1 directly contributes to HFD-induced bone loss, glucose handling impairment and obesity.